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Alzheimer’s disease (AD) sometimes presents with prominent executive dysfunction and 
associated prefrontal cortex atrophy. The impact of such executive deficits on episodic 
memory performance as well as their neural correlates in AD, however, remains unclear. 
This aim of the current study was to investigate episodic memory and brain atrophy in AD 
patients with relatively spared executive functioning (SEF-AD; n=12) and AD patients with 
relatively impaired executive functioning (IEF-AD; n=23). We also compared the AD 
subgroups with a group of behavioural-variant frontotemporal dementia patients (bvFTD; 
n=22), who typically exhibit significant executive deficits, and age-matched healthy controls 
(n=38). On cognitive testing, the three patient groups showed comparable memory profiles 
on standard episodic memory tests, with significant impairment relative to controls. Voxel-
based morphometry analyses revealed extensive prefrontal and medial temporal lobe 
atrophy in IEF-AD and bvFTD, whereas this was limited to the middle frontal gyrus and 
hippocampus in SEF-AD. Moreover, the additional prefrontal atrophy in IEF-AD and bvFTD 
correlated with memory performance, whereas this was not the case for SEF-AD. These 
findings indicate that IEF-AD patients show prefrontal atrophy in regions similar to bvFTD, 
and suggest that this contributes to episodic memory performance. This has implications for 
the differential diagnosis of bvFTD and subtypes of AD. 
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Alzheimer’s disease (AD) is a neurodegenerative disorder characterised clinically by 
progressive memory impairment and declines in language and visuospatial abilities [1]. A 
proportion of AD patients however, present with prominent executive dysfunction [2, 3], 
even during the early disease stages [4, 5].  
 
The cognitive profile of AD patients who present with executive dysfunction can be difficult 
to distinguish from patients with behavioural-variant frontotemporal dementia (bvFTD), 
who typically exhibit significant executive deficits [6]. In addition, bvFTD patients can also 
present with episodic memory impairment [7-9] and perform as poorly as AD patients on 
episodic memory tests [10-13]. Thus, overlap is present between AD and bvFTD in both 
executive and memory deficits, blurring the distinction between these two patient groups. 
Standard neuropsychological measures of executive function and episodic memory recall do 
not reliably distinguish between bvFTD and AD patients at presentation [14, 15]. 
Nevertheless, given that executive function is affected in some, but not all AD patients [2, 
16], it is unclear whether previous findings have been driven by deficits in a subset of 
dysexecutive AD patients.  
 
Previous studies comparing AD patients with or without prominent executive dysfunction 
have yielded mixed results. While some have reported similar levels of impairment on 
cognitive screening measures in both groups [4, 17], others have found executive-impaired 
AD patients to have significantly lower scores on cognitive and functional scales [2, 18, 19], 
with faster decline over time [20]. The impact of executive deficits on episodic memory in 
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AD also remains unclear, with some studies reporting worse performance on some memory 
tests in AD with executive dysfunction [17], but others finding no difference [4].  
 
Clinicopathological studies have identified pathologically confirmed cases of AD presenting 
with predominant executive dysfunction. The relative distribution of pathology in these 
cases appears to be markedly atypical, involving the frontal cortex as well as medial 
temporal lobe (MTL) structures [21, 22]. Neuroimaging investigations further indicate that 
AD patients who display frontal hypoperfusion tend to show a more dysexecutive profile, as 
well as worse neuropsychiatric symptoms and functional impairment compared to typical 
AD patients [23]. Furthermore, AD patients with prominent executive dysfunction show 
increased frontal hypometabolism [24] and additional cortical thinning in frontoparietal 
regions, despite equivalent cortical thinning in MTL regions compared to predominantly 
memory-impaired AD patients [25]. Similar findings have also been reported in dysexecutive 
versus amnestic mild cognitive impairment (MCI) patients, with greater frontal involvement 
in the former group [26, 27]. It is currently unknown, however, whether frontal atrophy in 
executive-impaired AD patients resembles the pattern of atrophy characteristically seen in 
bvFTD [28].  
 
This study addresses these issues by contrasting dysexecutive AD with bvFTD, with the aim 
of investigating the influence of executive function on memory, as well as identifying their 
neuroimaging correlates. Specifically, we compared episodic memory performance and 
brain atrophy between bvFTD patients and AD patients, who were classified into relatively 
spared and relatively impaired executive function subgroups (SEF-AD and IEF-AD), according 
to performance on standard neuropsychological tests of executive function. We also 
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compared the neural substrates of episodic memory performance in the three patient 
groups using voxel-based morphometry (VBM) covariate analyses. Based on previous 
evidence, we predicted that prefrontal cortex (PFC) and MTL atrophy would be least severe 
in SEF-AD patients, whereas IEF-AD and bvFTD patients would show more extensive atrophy 
in these regions. In addition, we expected that episodic memory performance would relate 
to divergent patterns of atrophy across the three groups, with greater PFC involvement in 
IEF-AD and bvFTD.  
 
Materials and Methods 
 
Case selection 
A total of 95 participants were selected from the FRONTIER database, at Neuroscience 
Research Australia, Sydney. The sample included 35 AD and 22 bvFTD patients and 38 age- 
and education-matched controls (see Table 1 for demographic details). Based on extensive 
clinical investigations, cognitive assessment and structural brain neuroimaging, patient 
diagnoses were established by consensus among a senior neurologist, neuropsychologist 
and occupational therapist. All patients met the relevant clinical diagnostic criteria for AD 
[1] or bvFTD [6]. Biomarker data were available and considered when assigning diagnoses in 
a subset of the patients, via positron emission tomography (PET) imaging for the amyloid-β 
ligand, Pittsburgh compound-B (PiB). Of those who underwent PiB-PET imaging, PiB-positive 
status was confirmed in 2/2 SEF-AD patients and 3/3 IEF-AD patients, whereas PiB-negative 
status was confirmed in 2/2 bvFTD patients. All patients were seen for follow-up, 
approximately 12 months following their initial visit. Only patients showing clear evidence of 
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disease progression in accordance with their diagnosis were included. Disease duration was 
estimated as the number of years elapsed since the onset of symptoms.  
 
The age- and education-matched healthy control group consisted of volunteers or 
spouses/carers of patients. Exclusion criteria included current or prior history of mental 
illness, significant head injury, movement disorders, cerebrovascular disease (stroke, 
transient ischemic attacks), alcohol and other drug abuse and limited English proficiency. 
 
Participants’ overall level of cognitive functioning was established using the Addenbrooke’s 
Cognitive Examination-Revised [ACE-R; 29]. The Frontotemporal Dementia Rating Scale [FRS; 
30] and Clinical Dementia Rating Scale [CDR; 31] were used as measures of the disease 
severity in bvFTD and AD patients. In addition, the Cambridge Behavioural Inventory-
Revised [CBI-R; 32] was used to quantify symptoms of behavioural disturbance reported by 
the family or carer, with higher scores indicative of more behavioural disturbance. All 
participants or their Person Responsible provided written informed consent in accordance 
with the Declaration of Helsinki. This study was approved by the South Eastern Sydney Local 
Health District and the University of New South Wales ethics committees.  
 
Measures of executive function 
The following neuropsychological tests of executive function were administered: the 
Backwards Digit Span test [DSB; 33], the Controlled Oral Word Association Test [COWAT; 
34], the Trail Making Test [TMT; 35] and the Hayling Sentence Completion Test [36].  
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The DSB test is a measure of working memory, where participants are required to repeat 
series of numbers (which increase in length over trials) in reverse order. The COWAT is a 
timed verbal fluency task that involves generating a list of words that begin with a specified 
letter (over 3 trials, for F, A or S). The total number of correct responses on the DSB test and 
total number of correct words on the COWAT were included in our analyses.  
 
The TMT is a measure of visual attention, psychomotor speed and cognitive flexibility. In 
Part A, participants are required to draw lines connecting numbers in a numerical sequence 
(1-2-3 etc.). This is followed by Part B, where participants are to draw lines connecting 
numbers and letters in an alternating numerical and alphabetical sequence (1-A-2-B-3-C 
etc.). Lines should be drawn as rapidly and accurately as possible and the time taken to 
complete each part is recorded, with a maximum time limit of 300 seconds for both 
sections. To obtain a measure of cognitive flexibility whilst accounting for psychomotor 
speed, Trails A time was subtracted from Trails B time (B-A time), with longer time indicative 
of greater impairment.  
 
The Hayling Sentence Completion Test assesses the ability to inhibit prepotent verbal 
responses on a sentence completion task. An initial baseline phase requires completion of a 
series of sentences with a logical word as quickly as possible. The second phase involves 
inhibition of the automatic logical response for a new set of sentences, and instead, 
completion with a word that is semantically unrelated. According the scoring criteria, errors 
were classed as belonging to Category A (highly related) or Category B (somewhat related), 
before conversion into an ‘A score’ and a ‘B score’. The sum of these scores (AB error score; 
maximum score=128) was included in our analyses.  
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Measures of episodic memory 
Following previously reported procedures [12, 37] verbal and visual episodic memory tests 
were administered to all participants. The Rey Auditory Verbal Learning Test (RAVLT) [38] 
was used to assess memory recall and recognition for verbal information. The RAVLT 
involves learning a list of 15 words (List A), which is read aloud over five consecutive trials, 
each followed by a free recall test. This is followed by presentation of an interference list of 
15 words (List B), with a free recall test for these words. Participants are then required to 
recall words from List A without further presentation (immediate recall trial A6). Following a 
30-minute delay, recall of List A is reassessed (delayed recall trial A7), followed by a 
recognition test, containing all items from List A as well as words from List B and 20 new 
words. Scores from trials A6 and A7 were included in our analyses. 
 
The Rey-Osterrieth Complex Figure Test [RCFT; 39] was administered to assess recall of 
visual information from a complex design. Three minutes after copying a complex figure as 
accurately as possible, participants were instructed to reproduce the figure from memory. 
The number of correctly recalled components (maximum score: 36) was included in our 
analyses. 
 
To investigate relationships between patterns of grey matter atrophy and episodic memory 
recall performance, a memory composite score was created. Episodic memory recall scores 
from the RAVLT trials A6 and A7 and RCFT were converted into percentage correct scores 
before averaging to yield the memory recall composite score, which was then included as a 
covariate in the imaging analyses.  
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Classification of AD patients 
Individual raw scores on the four executive tasks (TMT, COWAT, DSB and Hayling Test) were 
initially transformed into z-scores based on the mean and SD of the control group used in 
this study. Z-scores ≤ -1.5 (for COWAT and DSB total correct scores) or ≥ 1.5 (for TMT B-A 
time and Hayling Test AB error score) were classified to be within the impaired range. For 
the participants who were either unable to complete Part B of the TMT or failed to do so 
within the prescribed time limit (14.7% of participants; 10/35 AD and 4/22 bvFTD), the 
maximum Trails B time score of 300 seconds was used to compute their TMT B-A score. 
Following previously reported procedures [17, 40] AD patients who were impaired on 0 or 1 
of the executive tasks were classified as having spared executive function (SEF-AD; n = 12). 
In contrast, AD patients who were impaired on >1 of the executive tasks were classified as 
having impaired executive function (IEF-AD; n = 23).  
 
Statistical analyses 
Data were analysed using SPSS 20.0 (SPSS Inc., Chicago, Ill., USA). Kolmogorov-Smirnov tests 
were used to check for normality of distribution in the demographic data, 
neuropsychological measures of executive function and memory composite scores. Where 
the data were normally distributed, scores were compared across the four groups (SEF-AD, 
IEF-AD, bvFTD and controls) using ANOVAs followed by Tukey post hoc tests. Data that were 
not normally distributed were analysed using Kruskal-Wallis tests followed by post hoc 
pairwise comparisons, which were performed using Dunn’s [41] procedure with a 
Bonferroni correction for multiple comparisons. A chi-square test was used to check for 
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gender distribution across groups. Spearman rank correlations were used to investigate 
relationships between performance on measures of executive function and memory.  
 
Image acquisition and voxel-based morphometry (VBM) analysis 
All patients and controls underwent the same imaging protocol with whole-brain T1-
weighted images using a 3T Phillips MRI scanner with a standard quadrature head coil (8 
channels). The 3D T1-weighted sequences were acquired as follows: coronal orientation, 
matrix 256 x 256, 200 slices, 1 mm2 in-plane resolution, slice thickness 1mm, 
TE/TR=2.6/5.8ms. 3D T1-weighted sequences were analysed using FSL-VBM, a voxel-based 
morphometry analysis [42, 43], which is part of the FSL software package 
http://www.fmrib.ox.ac.uk/fsl/fslvbm/index.html [44]. Following brain extraction from the 
images, tissue segmentation was carried out using the FMRIB Automatic Segmentation Tool 
(FAST) [45]. The resulting gray matter partial volume maps were aligned to the Montreal 
Neurological Institute standard space (MNI52) using the nonlinear registration approach 
with FNIRT [46, 47], which uses a b-spline representation of the registration warp field [48]. 
To correct for local expansion or contraction, the registered partial volume maps were 
modulated by dividing them by the Jacobian of the warp field. The modulated images were 
then smoothed with an isotropic Gaussian kernel with a standard deviation of 3 mm 
(FWHM: 8mm). Because we had strong regional a priori, a single region of interest mask of 
PFC and MTL regions was created using the Harvard-Oxford cortical and subcortical 
structural atlas. The following regions were included in the mask: hippocampus, 
parahippocampal gyrus, fusiform cortex, temporal pole, precentral gyrus, superior frontal 
gyrus, middle frontal gyrus, inferior frontal gyrus, orbitofrontal gyrus, subcallosal cortex, 
medial prefrontal cortex, paracingulate gyrus, anterior cingulate gyrus and frontal pole.  
 11 
 
A voxel-wise general linear model (GLM) was applied to investigate differences in grey 
matter intensity via permutation-based non-parametric testing [49] with 5000 permutations 
per contrast. As a first step, differences in PFC and MTL grey matter intensity between 
patients (SEF-AD, IEF-AD and bvFTD) and controls were assessed. For comparisons between 
patients and controls, a threshold of 100 contiguous voxels was used, uncorrected at the 
p<.001 threshold. For analyses between patient groups, we lowered the cluster-based 
threshold to 75 contiguous voxels.  Next, correlations between memory performance and 
regions of grey matter atrophy were investigated in SEF-AD, IEF-AD and bvFTD patients 
combined with controls. This procedure has previously been used in similar studies including 
bvFTD and AD patients [12] and serves to achieve greater variance in test scores, thereby 
increasing the statistical power to detect brain-behaviour relationships. An overlap analysis 
was conducted to identify common regions of grey matter atrophy correlating with memory 
performance across groups. For all covariate analyses, a threshold of 100 contiguous voxels 
was used, uncorrected at the p<.001 threshold. Regions of significant grey matter density 
change were superimposed on the MNI standard brain, with maximum coordinates 
provided in MNI space, and localised with reference to the Harvard-Oxford probabilistic 




Demographics and global cognitive functioning 
Based on the criteria detailed in the Methods section, 12 AD patients were classified into 
the SEF-AD group and 23 AD patients into the IEF-AD group (Table 1). Participant groups 
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were matched for age, sex and education (all p values >.1). The three patient groups were 
matched for disease duration and dementia severity, as indexed by the CDR Sum of Boxes 
score (all p values >.1). As expected, bvFTD patients were significantly more impaired in 
comparison to both AD subgroups on a specific measure of FTD symptom severity (FRS 
Rasch score; SEF-AD vs. bvFTD, p<.001; IEF-AD vs. bvFTD, p<.05). On the cognitive screening 
test (ACE-R), all patient groups were significantly impaired in comparison to controls (all p 
values <.001) but did not differ from each other (all p values >.1). Analysis of the CBI-R 
subscores revealed significant differences across groups. Post hoc group comparisons 
indicated that relative to controls, SEF-AD patients showed more disturbance in memory 
and orientation, everyday skills, mood, stereotypic and motor behaviours and motivation (p 
values <.05). Compared to controls, IEF-AD patients had disturbance in relation to memory 
and orientation, everyday skills, mood and motivation (p values < .05). In comparison to 
controls, bvFTD patients showed more symptoms of behavioural disturbance across all CBI-
R subscores except abnormal beliefs (p values <.01). Post hoc comparisons between patient 
groups revealed more disturbance in eating habits in bvFTD relative to SEF-AD (p=.031) and 
IEF-AD (p<.001), as well as more symptoms of abnormal behaviour (p=.003), stereotypic and 
motor behaviours (p<.001) and reduced motivation (p=.015) in bvFTD relative to IEF-AD. 
Importantly, SEF-AD and IEF-AD patients did not differ on any of the CBI-R subscores (all p 
values >.05).  
 
Executive function 
Results for the executive function tests and correlations with memory performance are 




Results for the episodic memory recall raw scores (RAVLT trials A6 and A7, RCFT 3-minute 
recall trial) are detailed in Supplementary Information. These raw scores were averaged to 
yield a memory recall composite score. A main effect of group was found for the memory 
recall composite (F3,89=55.022, p<.001); see Figure 1. Tukey post hoc tests revealed that 
controls performed significantly higher than all patient groups (all p values <.001). 
Importantly, no significant differences were evident among the patient groups (all p values 
>0.1).  
 
VBM Group Analysis 
Patterns of atrophy 
Participant groups were contrasted to reveal patterns of PFC and MTL atrophy. Compared to 
controls, SEF-AD patients demonstrated relatively circumscribed atrophy in the right 
hippocampus and left inferior and middle frontal gyri (Figure 2A, Supplementary Table 3). 
IEF-AD patients showed atrophy relative to controls in the hippocampus bilaterally, as well 
as regions in the bilateral temporal and frontal poles, left inferior, middle and superior 
frontal gyri, left orbitofrontal cortex and left fusiform cortex (Figure 2B, Supplementary 
Table 3). In comparison to controls, bvFTD patients showed widespread bilateral atrophy, 
encompassing the hippocampus, frontal pole, orbitofrontal cortex, paracingulate cortex, 
subcallosal cortex, anterior cingulate cortex, medial prefrontal cortex, inferior, middle and 




Comparison of the SEF-AD and bvFTD groups indicated regions of greater atrophy in the 
latter group, involving the frontal pole, orbitofrontal cortex, paracingulate gyrus and 
superior frontal gyrus bilaterally, as well as left temporal pole and subcallosal cortex 
(Supplementary Figure 1A, Supplementary Table 4). In comparison to the IEF-AD group, 
bvFTD patients showed greater atrophy in the bilateral frontal and temporal poles, 
orbitofrontal cortex, subcallosal cortex, paracingulate cortex and superior frontal gyri 
(Supplementary Figure 1B, Supplementary Table 4). No PFC or MTL regions were found to 
be significantly more atrophic in IEF-AD or SEF-AD compared to bvFTD (Supplementary 
Table 4). Direct comparison of the two AD groups revealed significantly greater atrophy in 
the right superior frontal gyrus and frontal pole in the IEF-AD group (Supplementary Figure 
1C, Supplementary Table 4). The reverse contrast did not reveal any regions of significantly 
greater atrophy in SEF-AD compared to IEF-AD patients.  
 
Covariate analysis 
Memory composite scores were entered as covariates in the design matrix of the VBM 
analysis. For all participants combined, memory performance correlated with atrophy in the 
bilateral hippocampi, frontal and temporal poles, fusiform cortex, parahippocampal gyrus 
and orbitofrontal cortex, as well as the right medial prefrontal cortex, subcallosal cortex and 
superior temporal gyrus and left inferior, middle and superior frontal gyri and precentral 
gyrus (Supplementary Figure 2, Table 2). While memory performance in SEF-AD patients 
combined with controls correlated with a circumscribed region of atrophy in the right 
hippocampus (cluster size= 39 voxels; MNI coordinates X=28, Y=-14, Z=-18), this was below 
the uncorrected significance level of p<.001 and cluster threshold of 100 contiguous voxels 
(Figure 3A, Table 2).  In contrast, memory performance in IEF-AD patients combined with 
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controls covaried with bilateral regions of atrophy in the hippocampus and PFC, including 
orbitofrontal, medial prefrontal and paracingulate cortices. The left lateral frontal cortices 
were also implicated, including inferior, middle and superior frontal and precentral gyri, as 
well as the left temporal pole, fusiform cortex and parahippocampal gyrus (Figure 3B, Table 
2). In bvFTD patients combined with controls, memory performance correlated with 
bilateral regions of atrophy in the hippocampus, fusiform cortex, parahippocampal gyrus, 
temporal pole, orbitofrontal cortex, subcallosal cortex, medial prefrontal cortex, 
paracingulate cortex, superior frontal gyri and frontal pole (Figure 3C, Table 2). 
 
Next, we conducted an overlap analysis to investigate common regions of atrophy that 
underlie memory performance in IEF-AD and bvFTD (Figure 4, Table 3). This overlap analysis 
revealed that atrophy in the right frontal pole and bilateral hippocampi correlated 
significantly with memory performance in both the IEF-AD and bvFTD groups.  
 
A partial correlation analysis further explored whether atrophy in the prefrontal cortex 
could have explained the significant correlations with memory performance in IEF-AD and 
bvFTD. Indeed, PFC regions still correlated significantly (p<.001) with the memory composite 
score in IEF-AD patients, when MTL atrophy was taken into account. Similarly, in bvFTD 
patients, PFC regions remained significantly correlated (p<.05) with memory performance 








This study investigated the neuroimaging correlates of memory impairment in AD patients 
with or without executive dysfunction, compared to bvFTD patients, who typically show a 
dysexecutive cognitive profile. On cognitive testing, SEF-AD, IEF-AD and bvFTD patients 
showed substantial episodic memory impairments relative to age- and education-matched 
control participants, but did not differ from each other. Imaging analyses revealed that the 
pattern of prefrontal atrophy in IEF-AD patients was similar to that seen in bvFTD. 
Importantly, divergent neural correlates of memory performance were identified across 
groups. While hippocampal atrophy was associated with memory performance across all 
patient groups, additional prefrontal involvement was found only in IEF-AD and bvFTD. 
These findings shed light on important differences underlying the memory impairments in 
these patient groups. 
 
Converging evidence points to an atypical, frontal distribution of neuropathology in 
dysexecutive AD patients [21-25]. One significant contribution of the present study was the 
comparison of PFC and MTL atrophy between bvFTD patients and AD subgroups. Consistent 
with our hypothesis, imaging results indicate that the pattern of atrophy in IEF-AD 
resembles that seen in bvFTD patients, with bilateral involvement of the orbitofrontal and 
lateral prefrontal cortices, frontal pole as well as medial temporal regions. In contrast, SEF-
AD patients showed relatively circumscribed regions of PFC and MTL atrophy, involving the 
right hippocampus and left inferior and middle frontal gyri only. Our findings mesh well with 
a recent study by Woodward and colleagues [24], where ‘frontal’ AD patients showed 
greater medial and orbitofrontal cortex hypometabolism compared to other AD patients, 
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despite showing similar levels of hypometabolism in the lateral prefrontal regions. 
Furthermore, the widespread prefrontal atrophy seen in our IEF-AD group is consistent with 
previous reports of cortical thinning [25], AD-type pathology and neuronal loss [21, 22] in 
the frontal lobes of dysexecutive AD patients. It is important to note, however, that PFC 
atrophy was more extensive in bvFTD compared to IEF-AD, despite the involvement of 
similar regions in these two patient groups. This is consistent with the typical pattern of 
atrophy reported in bvFTD [50]. 
 
On a cognitive level, our findings are consistent with a number of studies that have 
identified significant executive deficits in a subgroup of AD patients, using specific tests of 
executive function [2-4, 17, 51]. In keeping with previous studies [10-12, 37], episodic 
memory performance was similarly impaired in both AD and bvFTD. Furthermore, it was not 
possible to distinguish between SEF-AD and IEF-AD solely based on episodic memory 
performance. While this could be due to floor effects across all AD patients, it is also 
possible that measures of memory recall on the RAVLT and RCFT are not sensitive enough to 
detect the additional impact of executive deficits observed in the IEF-AD group.  
 
Importantly, our findings extend prior research by demonstrating that poor memory 
performance in SEF-AD and IEF-AD is mediated by divergent patterns of PFC and MTL 
atrophy. While memory impairments were related to hippocampal atrophy in both AD 
subgroups, this showed additional associations with prefrontal atrophy in IEF-AD patients 
only. Similarly, prefrontal atrophy was related to memory performance in bvFTD. Our 
finding of PFC involvement in memory impairments in IEF-AD and bvFTD challenges the 
notion that different neural processes underlie memory dysfunction in AD and bvFTD. As 
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such, it has often been presumed that poor memory performance in AD is due to deficits in 
memory consolidation, a  process presumed to be mediated by the medial temporal lobes 
[52]. On the other hand, memory impairment in bvFTD is generally thought to be secondary 
to deficits in the executive aspects of memory, including planning and organisation of 
information, monitoring and inhibition of responses and contextual memory [53]. Hence, 
this dichotomous view does not take into the account the contribution of frontally-
mediated executive deficits to memory dysfunction in IEF-AD. In light of the significant PFC 
involvement in memory performance in IEF-AD but not SEF-AD, our findings point to 
important differences in the neural mechanisms underlying memory impairments in these 
AD subgroups.  
 
Another novel finding to emerge from this study was the identification of shared prefrontal 
neural correlates of memory dysfunction in IEF-AD and bvFTD. Although atrophy in several 
PFC subregions correlated with memory performance in IEF-AD and bvFTD separately, the 
right lateral frontal pole was the only subregion commonly implicated across both patient 
groups. While associations between frontal polar atrophy and episodic memory 
performance have previously been reported in AD and bvFTD [12, 15], the specific 
mechanism through which this prefrontal subregion contributes to memory impairments in 
IEF-AD and bvFTD remains, to date, underexplored. Interestingly, the frontal pole (otherwise 
known as the rostral prefrontal cortex or Brodmann’s Area 10) appears to be involved in 
various higher-order cognitive functions, with further functional specializations within its 
subregions. As such, the lateral frontal pole has been implicated in working memory and 
episodic memory retrieval, whereas medial regions are involved in mentalizing [54]. 
Furthermore, several studies have revealed divergent patterns of functional connectivity 
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across different frontal polar subregions, with strong projections between the lateral frontal 
pole and nodes of the executive control network, such as the dorsolateral prefrontal cortex 
and supplementary motor area [55, 56]. In light of evidence from neuroimaging studies, 
which implicate the dorsolateral prefrontal cortex in executive aspects of episodic memory 
recall [57, 58], it seems likely that the right lateral frontal polar involvement in memory 
performance in IEF-AD and bvFTD patients reflects the impact of their executive deficits on 
memory impairment, which needs further investigation in the future.  
 
Our imaging analyses also revealed varying degrees of MTL involvement in memory 
performance across the three patient groups. In the SEF-AD group, hippocampal atrophy 
correlated with memory performance, but this was below the statistical threshold applied in 
our analyses. This likely reflects the relatively circumscribed pattern of MTL atrophy found 
in this group. Surprisingly, although MTL regions correlated with memory performance in 
both IEF-AD and bvFTD, this was more extensive in bvFTD. In this context, it is important to 
note that our imaging results were a priori masked for prefrontal and medial temporal 
regions. Therefore, other brain regions may have contributed to the observed memory 
deficits. In particular, the precuneus and posterior cingulate cortex have been shown to play 
a relatively large role in memory impairment in AD [12, 59], as well as diencephalic atrophy 
[60]. These regions were, however, not included in our imaging analyses and as such, 
further exploration of the relative contributions of other brain regions to memory 
dysfunction in these patient groups is warranted. 
 
Given that both PFC and MTL regions correlated with memory performance in IEF-AD and 
bvFTD, our findings suggest that memory impairments in these patients are not only due to 
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hippocampal but also frontal dysfunction. Along a similar vein, Bertoux, et al. [13] revealed 
two distinct profiles of episodic memory dysfunction in bvFTD, using the Free and Cued 
Selective Reminding Test (FCSRT). While one subgroup demonstrated impaired memory 
consolidation, consistent with the characteristic profile of memory impairments in AD, 
another subgroup showed deficits in the strategic aspects of memory recall, such that they 
benefited from cueing. The authors concluded that memory impairments in bvFTD may not 
be solely attributable to executive dysfunction. Although our memory measures did not 
allow this dissociation, our imaging findings, which indicate both PFC and MTL involvement, 
dovetail with this result. Given the overlap in executive deficits and memory impairment in 
IEF-AD and bvFTD, the implementation of memory measures that can disentangle these 
prefontally- and hippocampally-driven memory processes represents an important area of 
future inquiry. 
 
Overall, our findings provide further support to the notion that memory impairments in AD 
and bvFTD are not solely driven by deficits in hippocampal or prefrontal memory processes, 
respectively. Indeed, the cooperative involvement of both PFC and MTL structures has been 
purported to be necessary for memory functioning in AD and bvFTD, with greater 
involvement of PFC regions in bvFTD [11, 37]. The current study extends existing findings by 
demonstrating PFC involvement in memory impairment in a subgroup of AD patients who 
show distinct profiles of executive dysfunction and prefrontal atrophy.  
 
From a clinical perspective, the potential overlaps in executive and memory impairments in 
AD and bvFTD call into question the diagnostic value of conventional measures of executive 
function and memory that are commonly used in clinical settings. Our findings add to a 
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growing body of literature, which indicates that deficits in these areas are not specific to 
either disease and therefore, do not reliably distinguish between bvFTD and AD. Yet, current 
diagnostic criteria for bvFTD describes a predominantly dysexecutive cognitive profile, with 
relative sparing of episodic memory [6]. On the other hand, revised criteria for AD allow for 
atypical presentations with prominent executive dysfunction [1], yet this so-called ‘frontal 
AD’ can be clinically misdiagnosed as bvFTD [22, 61]. We and others [15, 62-64] have 
suggested that tests of social cognition may better distinguish between AD and bvFTD, as 
these measures target medial prefrontal cortex regions that are predominantly affected in 
bvFTD [28, 64]. In light of the present findings, it is unclear whether IEF-AD patients would 
have similar social-cognitive deficits, given that they show patterns of prefrontal atrophy in 
similar regions as bvFTD patients. Speculatively, it is possible that IEF-AD and bvFTD patients 
may be distinguishable on measures of social cognition and behavioural symptoms, 
although one previous study that did include these measures showed that ‘frontal AD’ 
patients could be impaired [51]. This should be addressed in future research, as 
improvements in diagnostic accuracy will help guide potential treatment choices in these 
patient groups.  
 
A number of caveats warrant further discussion. Firstly, we did not have neuropathological 
confirmation for the clinical diagnoses, as the majority of our sample had not yet come to 
autopsy. As such, we cannot exclude the possibility that some bvFTD patients had 
underlying AD pathology and vice versa. Indeed, findings from several postmortem studies 
indicate that multiple pathologies may co-occur [65, 66]. Reassuringly, bvFTD patients 
showed a higher prevalence of behavioural symptoms on the CBI-R, including abnormal 
behaviour, stereotypic and motor behaviours, apathy and abnormal eating habits. 
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Furthermore, our patient sample included only those who showed clear evidence of disease 
progression in accordance with their diagnosis, within a minimum 12-month follow-up 
period. Nevertheless, our findings mesh well with a growing number of studies highlighting 
memory impairments in neuropathologically confirmed cases of bvFTD [8, 60], and 
executive dysfunction in neuropathologically confirmed cases of AD [20, 21].  
 
Secondly, although measures of disease duration, dementia severity and behavioural 
disturbance were not statistically different between our two AD subgroups, IEF-AD patients 
tended to have longer duration and greater severity of symptoms. Additionally, given that 
estimated symptom onset was based on caregiver reports, the potential for overestimating 
disease duration may have differed for those with more dysexecutive symptoms. Taken 
together with our relatively small sample size, the possibility that IEF-AD patients represent 
a subgroup of AD patients with more advanced disease progression cannot be ruled out. 
Nonetheless, we and others [16, 25] have shown divergent patterns of prefrontal atrophy in 
AD patients presenting with or without significant executive dysfunction. Whether this 
represents typical neuropathological progression in more advanced stages of AD or an 
altogether different trajectory of degeneration in IEF-AD remains to be addressed. As such, 
replication of our findings in a larger patient cohort, in conjunction with longitudinal clinical 
and neuroimaging data, represents an important area of future enquiry. 
 
Another limitation of this study concerns the range of executive abilities assessed by the 
tests included in our battery, which encompassed working memory, verbal response 
inhibition and cognitive flexibility. Future studies should incorporate a broader battery to 
include problem solving and reasoning skills. Furthermore, as age- and education-adjusted 
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normative data were not available for some executive measures, analyses were conducted 
using z-scores derived from control data. While the control and patient groups were 
matched in terms of age and level of education, this could potentially limit the applicability 
of our findings in other cohorts. In spite of these limitations however, our delineation of the 
AD subgroups point to important differences in the brain regions implicated in memory 
impairment in AD patients presenting with or without significant executive dysfunction.  
 
Finally, although our findings suggest that both hippocampal and prefrontal mechanisms 
contribute to memory performance in both IEF-AD and bvFTD, our memory recall composite 
did not allow for distinctions to be made between these processes. More detailed 
investigations with measures that can tap into such aspects of memory function in these 
patient groups are therefore warranted. For example, the California Verbal Learning Test-
Second Edition [67] yields process scores that assess executive aspects of memory, including 
semantic clustering, cued recall and discrimination indices for word and source recognition. 
Similarly, employing the Boston Qualitative Scoring System [68], which assesses planning, 
fragmentation, neatness, perseveration and organisation on the RCFT, could provide further 
insights into the relationship between the executive aspects of visual memory encoding and 
subsequent recall performance. 
 
 With these caveats in mind, this study provides additional evidence that a subgroup of AD 
patients have significant executive deficits and prefrontal atrophy in similar regions to those 
affected in bvFTD. Although profiles of memory dysfunction were indistinguishable in SEF-
AD, IEF-AD and bvFTD, our findings reveal divergent neural correlates of memory 
impairment in these patient groups, with prefrontal involvement in the latter two groups 
 24 
only. Taken together, considerable overlap exists between IEF-AD and bvFTD patients in 
terms of performance on memory and executive function tests, as well as neuroimaging 
measures of atrophy and neural correlates of memory dysfunction. Our findings have 
important clinical implications in that current measures of memory and executive function 
may lack sufficient sensitivity to distinguish between IEF-AD and bvFTD.  
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Table 1. Demographic characteristics across participant groupsa 
 Control SEF-AD IEF-AD bvFTD F Post hoc 
Age (years) 65.58 (5.53) 65.17 (7.87) 63.91 (7.87) 60.95 (6.24) n.s.  
       
Gender (M:F) 19:19 6:6 13:10 17:5 n.s.  
Education (years) 12.5 (2.39) 12.25 (3.79) 12.5 (3.25) 11.83 (3.18) n.s.  
Disease duration (years) - 3.13 (1.19) 3.41 (2.10) 3.57 (2.14) n.s.  
FRS Rasch score - 1.74 (0.94) 0.78 (1.69) -0.36 (0.98) *** SEF-AD, IEF-AD > bvFTD 
CDR sum of boxes score [18] 0.42 (0.53) 3.55 (1.77) 3.93 (2.13) 5.60 (2.60) *** SEF-AD, IEF-AD, bvFTD > Controls 
ACE-R total [100] 95.21 (3.48) 80.92 (7.25) 72.78 (7.62) 76.32 (11.75) *** SEF-AD, IEF-AD, bvFTD > Controls 
CBI-R subscores [100]       
Memory and orientation 5.41 (6.59) 47.73 (14.73) 45.92 (25.22) 42.69 (18.27) *** SEF-AD, IEF-AD, bvFTD > Controls 
Everyday skills 0.42 (1.40) 15.00 (17.32) 28.64 (25.36) 29.52 (22.80) *** SEF-AD, IEF-AD, bvFTD > Controls 
Self-care 0 2.27 (5.06) 4.62 (9.83) 8.33 (15.22) ** bvFTD > Controls 
Abnormal behaviour 3.13 (7.48) 11.74 (10.34) 9.60 (10.77) 36.59 (23.72) *** bvFTD > Controls, IEF-AD 
Mood 1.73 (4.12) 17.61 (17.41) 17.39 (18.84) 26.19 (22.67) *** SEF-AD, IEF-AD, bvFTD > Controls 
Beliefs 0 2.27 (3.89) 3.08 (12.19) 3.97 (11.96) * n.s. 
 31 
Eating habits 3.30 (7.97) 13.64 (18.71) 9.24 (13.96) 38.39 (25.02) *** bvFTD > SEF-AD, IEF-AD, Controls 
Sleep 13.19 (16.08) 22.73 (18.39) 29.89 (29.61) 39.29 (32.66) * bvFTD > Controls 
Stereotypic/motor 
behaviours 
6.60 (14.48) 24.43 (21.55) 13.59 (19.28) 53.57 (28.82) *** SEF-AD > Controls; bvFTD > IEF-AD, Controls 
Motivation 1.81 (5.99) 25.91 (25.28) 18.80 (17.74) 62.38 (35.52) *** SEF-AD, IEF-AD, bvFTD > Controls; bvFTD > IEF-AD 
a Standard deviations in parentheses, maximum score for tests shown in brackets. 
Frontotemporal Dementia Rating Scale (FRS); Clinical Dementia Rating Scale (CDR); Addenbrooke’s Cognitive Examination-Revised (ACE-R); 
Cambridge Behavioural Inventory-Revised (CBI-R). 


















of voxels X Y Z 
All groups 
     Temporal pole, orbitofrontal cortex, inferior frontal gyrus, middle frontal gyrus, 
frontal pole, fusiform cortex (anterior), parahippocampal gyrus (anterior and 
posterior), hippocampus L -40 4 -46 3075 
Medial prefrontal cortex, frontal pole R 2 46 -26 1323 
Fusiform cortex (posterior), parahippocampal gyrus (anterior and posterior), 
hippocampus R 40 -22 -36 1194 
Orbitofrontal cortex, subcallosal cortex, medial prefrontal cortex R 12 30 -18 300 
Superior frontal gyrus, precentral gyrus L -20 -16 54 192 
Superior temporal gyrus (anterior), temporal pole,  R 62 6 -12 128 
SEF-AD and controls      
None above threshold      
 33 
IEF-AD and controls      
Frontal pole R 28 52 -8 760 
Orbitofrontal cortex, medial prefrontal cortex, paracingulate gyrus, frontal pole B 8 32 -28 646 
Orbitofrontal cortex, frontal pole, inferior frontal gyrus L -26 18 -10 465 
Superior frontal gyrus, precentral gyrus L -20 -16 56 296 
Hippocampus L -22 -16 -22 258 
Temporal pole L -56 4 -14 251 
Hippocampus R 28 -14 -24 186 
Fusiform cortex (anterior and posterior), parahippocampal gyrus (anterior) L -30 -12 -40 152 
Middle frontal gyrus, inferior frontal gyrus L -40 12 30 109 
bvFTD and controls      
Fusiform cortex (anterior and posterior), parahippocampal gyrus (anterior and 
posterior), hippocampus, temporal pole, orbitofrontal cortex, subcallosal cortex, 
medial prefrontal cortex, frontal pole B -26 -8 -48 6184 
Frontal pole, paracingulate gyrus, superior frontal gyrus B 12 72 -8 1863 
Orbitofrontal cortex R 26 20 -10 163 
 34 
Superior frontal gyrus L -4 18 56 115 















Table 3. Voxel-based morphometry results showing common regions of significant grey matter intensity decrease that correlate with memory 







of voxels X Y Z 
Frontal pole R 24 62 6 202 
Hippocampus R 28 -14 -24 159 
Hippocampus L -22 -16 -20 151 
 








Figure 1. Mean memory recall performance (memory composite score) in controls, spared 
executive function Alzheimer’s disease (SEF-AD), impaired executive function Alzheimer’s 
disease (IEF-AD) and behavioural-variant frontotemporal dementia (bvFTD) participants. 
Error bars represent standard error of the mean. ***p<.001.  
 
 
Figure 2. VBM analyses showing brain regions of decreased grey matter intensity in (A) SEF-
AD patients in comparison with controls (B) IEF-AD patients in comparison with controls and 
(C) bvFTD patients in comparison with controls. Coloured voxels show regions that were 
significant in the analyses with p<.001, uncorrected for all contrasts, with a cluster threshold 
of 100 contiguous voxels. Clusters are overlaid on the MNI standard brain.  
 
 
Figure 3. VBM analyses showing brain regions in which grey matter intensity correlates 
significantly with memory recall performance in (A) SEF-AD compared with controls, (B) IEF-
AD compared with controls and (C) bvFTD compared with controls. Coloured voxels show 
regions that were significant in the analysis with p<.001 uncorrected, with a cluster 




Figure 4. VBM analyses showing brain regions in which grey matter intensity correlates 
significantly with memory recall performance in both IEF-AD and bvFTD. Coloured voxels 
show regions that were significant in the analysis with p<.001 uncorrected, with a cluster 
threshold of 100 contiguous voxels. Clusters are overlaid on the MNI standard brain.  
